Time to get long GILD
Gilled is an extremely strong company fundamentally with huge earnings growth. Stock was hid with uncertainty with competition or ABBY but their new Hep C drugs should still control 80-90% of market share. Also the retracement off the recent high has found solid support at the $100 level. The stock looks ready for a move higher
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.